Table 4.

Adjusteda OR and 95% CIs for associations of regular aspirin use with prostate cancer in men with low stageb disease compared with population controls

TotalAAEA
ControlCasecOR (95% CI)ControlCaseOR (95% CI)ControlCaseOR (95% CI)
Did you take aspirin regularly 1 year prior to interview?
 No441 (46)347 (53)Ref.233 (52)199 (61)Ref.208 (40)148 (47)Ref.
 Yes529 (54)310 (47)0.84 (0.68–1.04)220 (48)140 (39)0.79 (0.57–1.09)309 (60)170 (53)0.84 (0.62–1.14)
In the past 5 years, did you take at least 1 tablet daily?
 No467 (46)362 (52)Ref.242 (50)209 (58)Ref.225 (42)153 (46)Ref.
 Yes556 (54)336 (48)0.88 (0.72–1.09)239 (50)153 (42)0.76 (0.56–1.03)317 (58)183 (54)0.95 (0.71–1.28)
In the past 5 years, how long did you regularly take aspirin?
 Did not use441 (43)347 (50)Ref.233 (49)199 (55)Ref.208 (39)148 (45)Ref.
 ≤3 years174 (17)126 (18)0.95 (0.72–1.26)89 (19)64 (18)0.84 (0.56–1.26)85 (16)62 (18)1.06 (0.71–1.59)
 >3 years401 (39)222 (32)0.82 (0.65–1.03)157 (33)97 (27)0.76 (0.53–1.09)244 (45)125 (37)0.81 (0.59–1.12)
Ptrend = 0.10Ptrend = 0.13Ptrend = 0.20
Among users who took at least 1 tablet daily, how long did they regularly take aspirin?
 Did not use467 (46)362 (51)Ref.242 (51)209 (58)Ref.225 (42)153 (46)Ref.
 ≤3 years158 (16)118 (17)1.01 (0.76–1.35)82 (17)58 (16)0.81 (0.54–1.24)76 (14)60 (18)1.22 (0.81–1.83)
 >3 years390 (38)214 (32)0.82 (0.65–1.04)154 (32)93 (26)0.72 (0.50–1.03)236 (44)121 (36)0.85 (0.62–1.18)
Ptrend = 0.10Ptrend = 0.06Ptrend = 0.34
  • NOTE: Column total sums that differ are due to missing data, N (%).

  • aUnconditional logistic regression adjusted for age at study entry, BMI (kg/m2), diabetes (yes/no), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes/no), race (not included in stratified analysis), smoking history (never, former, current), Tylenol (yes/no), and pain relievers not containing Tylenol or aspirin-containing compounds (yes/no).

  • bLow stage includes men with pathologically confirmed T1 or T2 disease.

  • cCases recruited within 1 year after disease diagnosis with an average interval between diagnosis and enrollment of 4.8 months.